2025 United Kingdom Anti-Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 United Kingdom Anti-Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies active in the anti-migraine drugs market in the United Kingdom include AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Eli Lilly and Company. AbbVie markets Qulipta, a daily oral preventive treatment for migraines, and has expanded its operations internationally with this product. Amgen is known for anti-CGRP monoclonal antibodies used in migraine prevention. Teva Pharmaceuticals also plays a key role with AJOVY (fremanezumab), targeting both adult and pediatric migraine prevention, and recently confirmed efficacy in clinical trials. Eli Lilly collaborates with Organon to distribute Emgality (galcanezumab) and Rayvow (lasmiditan) in Europe, which includes the UK.
Additionally, Biohaven Pharmaceuticals is notable for Nurtec ODT, a dual-acting medication for acute and preventive migraine treatment. Lundbeck A/S is another major player innovating with CGRP and PACAP inhibitors such as Vyepti and new monoclonal antibodies in development. These companies invest heavily in R&D, developing novel therapies aimed at both acute symptom relief and prevention of migraines, addressing significant patient unmet needs in the UK market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies active in the anti-migraine drugs market in the United Kingdom include AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Eli Lilly and Company. AbbVie markets Qulipta, a daily oral preventive treatment for migraines, and has expanded its operations internationally with this product. Amgen is known for anti-CGRP monoclonal antibodies used in migraine prevention. Teva Pharmaceuticals also plays a key role with AJOVY (fremanezumab), targeting both adult and pediatric migraine prevention, and recently confirmed efficacy in clinical trials. Eli Lilly collaborates with Organon to distribute Emgality (galcanezumab) and Rayvow (lasmiditan) in Europe, which includes the UK.
Additionally, Biohaven Pharmaceuticals is notable for Nurtec ODT, a dual-acting medication for acute and preventive migraine treatment. Lundbeck A/S is another major player innovating with CGRP and PACAP inhibitors such as Vyepti and new monoclonal antibodies in development. These companies invest heavily in R&D, developing novel therapies aimed at both acute symptom relief and prevention of migraines, addressing significant patient unmet needs in the UK market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
